SM
PTCT icon

Sabby Management’s PTC Therapeutics PTCT Stock Holding History

Sabby Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-54,736
Closed -$737K – 250
2017
Q1 		$539K Buy
+54,736
New +$663K 0.03% 174
2015
Q4 		– Sell
-23,387
Closed -$688K – 358
2015
Q3 		$624K Buy
+23,387
New +$1M 0.03% 278

Other funds holding PTCT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Sabby Management's PTCT Position: Q2 2017 in Review

Sabby Management sold out of PTC Therapeutics (PTCT) in Q2 2017, closing a stake of 54,736 shares — an estimated $737K sold.

Sabby Management first reported a position in PTCT in Q3 2015 and held it in 2 quarters. The position peaked at $624K in Q3 2015. 114 funds tracked by Wall St. Rank hold PTCT as of Q2 2017.

  • Sabby Management reported no remaining PTC Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Sabby Management sold 54,736 PTC Therapeutics shares in Q2 2017, an estimated $737K.
  • Sabby Management first reported a position in PTC Therapeutics in Q3 2015 and held it in 2 quarters.
  • Sabby Management's PTC Therapeutics position peaked at $624K in Q3 2015.
  • 114 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2017.

Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.